Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Sociedade Brasileira de Cirurgia Cardiovascular
2025
|
| Soggetti: | |
| Accesso online: | https://www.redalyc.org/articulo.oa?id=398982402015 https://www.redalyc.org/journal/3989/398982402015/ https://www.redalyc.org/journal/3989/398982402015/html/ https://www.redalyc.org/journal/3989/398982402015/398982402015.epub https://www.redalyc.org/journal/3989/398982402015/movil |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Earlyto Mid-Term Results of Aortic Valve Neocuspidization for Rheumatic Aortic Valve Disease Mohamed Sanad Mohamed Gabr Ahmed ElDerie Hatem Beshir Mohamed Hegazy Mohammed Abdallah Sameh M. Said Medicina Reoperation Coronavirus Patient Discharge Cardiopulmonary Bypass Rheumatic Heart Disease Recently, there has been a widespread use of aortic valve neocuspidization, but there is limited data regarding rheumatic heart disease. In this study, we reviewed our experience. Methods: A total of 33 patients (22 men, 66.7%) with rheumatic aortic valve disease (mean age 39.36 ± 10.65 years) underwent aortic valve replacement between June 2019 and October 2023. Results: The most common pathology was severe stenosis (14 patients, 42.4%), with bicuspid morphology in 11 patients (33.3%). The mean cardiopulmonary bypass and aortic cross-clamping times were 151 ± 24.26 and 127 ± 21.05 minutes, respectively. There was no perioperative mortality. One patient who developed significant aortic regurgitation underwent valve replacement prior to discharge. The pre-discharge average peak/mean gradients were 12 ± 3.7/6 ± 2 mmHg, respectively. Follow-up was complete (mean: 31.54 ± 12.94 months). There were two late mortalities (6%), one due to endocarditis and another due to coronavirus disease. One patient (3%) needed a permanent pacemaker one year later. Overall survival at one, two, and four years were 97%, 97%, and 94% respectively, and freedom from reoperation was consistent at 97%. The peak/mean gradients remained low at one and three years (12 ± 2.7 mmHg/4.8 ± 1.7 mmHg and 10.14 ± 4.02/4.4 ± 2.3 mmHg, respectively). Overall four-year freedom from at least moderate regurgitation was 97%. Conclusion: Our data shows promising results for this procedure in rheumatic pathology. The hemodynamic data is satisfactory and the early- to mid-term results are encouraging; however, long-term data is needed to determine durability. 2025 artículo científico 0102-7638 https://www.redalyc.org/articulo.oa?id=398982402015 https://www.redalyc.org/journal/3989/398982402015/ https://www.redalyc.org/journal/3989/398982402015/html/ https://www.redalyc.org/journal/3989/398982402015/398982402015.epub https://www.redalyc.org/journal/3989/398982402015/movil 10.21470/1678-9741-2024-0412 en http://www.redalyc.org/revista.oa?id=3989 Revista Brasileira de Cirurgia Cardiovascular/Brazilian Journal of Cardiovascular Surgery application/pdf Sociedade Brasileira de Cirurgia Cardiovascular Revista Brasileira de Cirurgia Cardiovascular/Brazilian Journal of Cardiovascular Surgery (Brasil) Num.5 Vol.40